Clinical Trial Update: Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial investigating donor-derived CMVpp65 specific T-cells for treatment of CMV infection or persistent CMV viremia after allogeneic hematopoietic stem …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Disease
• Cytomegalovirus Infection

Drugs mentioned

• CMVpp65-specific T cells (CMV pp65-specific cytotoxic T lymphocytes)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Cytomegalovirus | Phase 2 | Status: COMPLETED | Results posted: 2020-12-16